Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

44 results about "Buprenophine" patented technology

Injectable buprenorphine formulation

ActiveUS20250041205A1Organic active ingredientsNervous disorderMaintenance therapyOrganic solvent
The present invention provides an injectable liquid formulation comprising:a) a lipid controlled-release matrix comprising at least 50% triacyl lipids;b) at least one oxygen containing organic solvent;c) at least 16% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The invention further provides a controlled-release composition formed by administration of such an injectable liquid composition to a, preferably human, subject. The invention also provides a method of administration of buprenorphine to a subject comprising injecting such a liquid composition and a method for the treatment of pain, for opioid maintenance therapy or for the treatment of opioid dependence by detoxification and / or maintenance or for the treatment or prophylaxis of the symptoms of opioid withdrawal and / or cocaine withdrawal by injecting such a liquid composition.
Owner:CAMURUS AB

Opioid formulations

A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
Owner:CAMURUS AB

Long-acting injectable formulations and crystalline forms of buprenorphine derivatives

This disclosure relates to crystalline forms of 3-acyl-buprenorphine derivatives and sustained release injectable pharmaceutical compositions for treatment of opioid dependence, pain or depression, including an aqueous suspension of crystalline 3-acyl-buprenoprhine, or a pharmaceutically acceptable salt thereof, wherein the composition does not include an organic solvent, a polylactide polymer, a polyglycolide polymer, or a copolymer of polylactide and polyglycolide. This disclosure also includes 3-acyl-buprenoprhine or a pharmaceutically acceptable salt thereof prepared in a controlled release matrix, including poly(lactide-co-glycolide), sucrose acetoisobutyrate, lecithin, diolein and a combination of two or more thereof.
Owner:ALAR PHARMA INC

Deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure

Disclosed herein is deuterated buprenorphine as a protective agent for fetal subjects against full-agonist opioid exposure. Use of deuterated buprenorphine prevents or reduces exposure of the fetus to opioids used by the mother. Use of deuterated buprenorphine may prevent or reduces exposure of the fetus to harmful metabolites of buprenorphine.
Owner:BIOVENTURES LLC

Treatment of chronic pain or gastrointestinal disorders using buprenorphine dimers

PendingJP2026525291ADiseaseDimer
This disclosure provides a method for treating a disease in a subject requiring treatment, such as chronic pain or IBS-D, the method of treating the disease by orally administering i) a therapeutically effective amount of buprenorphine dimer, or ii) a pharmaceutical composition comprising a therapeutically effective amount of buprenorphine dimer, wherein the buprenorphine dimer is represented by formula (I) or a pharmaceutically acceptable salt thereof. In particular, the administered buprenorphine dimer of formula (I) is in a neutral form. A method for producing a neutral form of buprenorphine dimer is also described.
Owner:ディマークス インコーポレイティド

Stable pharmaceutical composition of buprenorphine, preparation method and application thereof

The present disclosure provides a pharmaceutical composition comprising buprenorphine, a derivative thereof, or a pharmaceutically acceptable salt thereof, a stabilizer, a biocompatible solvent, and at least one compound represented by Formula (IIA), Formula (IIB), or Formula (IIC) wherein R1 is hydrogen, C1-C20 alkylcarbonyl, or C6-C18 arylcarbonyl, and wherein within the shelf life of the pharmaceutical composition, R1 is hydrogen, C1-C20 alkylcarbonyl, or C6-C18 arylcarbonyl, R2 is hydrogen, C1-C20 alkylcarbonyl, or C6-C18 arylcarbonyl, and R3 is hydrogen, C1-C20 alkylcarbonyl, or C6-C18 arylcarbonyl. The amounts of the compounds of formula (IIA), formula (IB), and formula (IIC) are each less than 1% w / w based on the total weight of the pharmaceutical composition. The disclosure also provides a method of making the pharmaceutical composition and a method of administering the pharmaceutical composition to a subject in need thereof to treat opioid addiction, pain, and / or depression. # imgabs0 #
Owner:ALAR PHARMA INC

Treatment of chronic pain or gastrointestinal disorders using buprenorphine dimers

The present disclosure provides a method of treating a disease (e.g., chronic pain or IBS-D) in a subject in need thereof by oral administration: i) a therapeutically effective amount of buprenorphine dimer; or ii) a pharmaceutical composition comprising a therapeutically effective amount of the buprenorphine dimer wherein the buprenorphine dimer is represented by Formula (I): or a pharmaceutically acceptable salt thereof, in particular, the administered buprenorphine dimer of Formula (I) is in a neutral form, methods of preparing the buprenorphine dimer in neutral form are also described.
Owner:戴梅克斯公司

Preparation of Buprenorphine

PendingUS20250263419A1Organic chemistryPharmacologyBuprenophine
Disclosed are methods for preparing buprenorphine from, for example, compounds such as nororipavine and northebaine.
Owner:RIVER STONE BIOTECH APS

Method of treatment and dosage forms thereof

The invention provides an oral dosage form comprising(i) an amount of oxycodone and(ii) an amount of buprenorphine,wherein the weight ratio of the amount of buprenorphine to the amount of oxycodone is greater than 1:40 calculated with the amount of buprenorphine in the dosage form expressed as the equimolar amount of buprenorphine base (Mw=467.64 g / mol) in mg, and the amount of oxycodone in the dosage form expressed as the equimolar amount of oxycodone hydrochloride (Mw=351.82 g / mol) in mg. The invention also provides combinations of an opioid agonist and buprenorphine for use to treat pain, wherein the combination achieves a reduction of adverse pharmacodynamic responses (such as, respiratory depression), compared with a corresponding stand-alone opioid therapy. The invention also includes methods of treatment and dosage forms thereof comprising such combinations.
Owner:PURDUE PHARMA LP

Methods for improving production of morphinan alkaloids and derivatives

Disclosed herein are methods useful for the synthesis of benzylisoquinoline alkaloids ("BIA"), such as alkaloid morphinans. The disclosed methods can be used to produce thebaine, eastern papaverine, codeine, morphine, oxycodone, hydrocodone, oxymorphinone, hydromorphinone, naltrexone, naloxone, hydroxycodeinone, neolpinone, and / or buprenorphine.
Owner:ANSIYA CORP

Buprenorphine crystal form and preparation method thereof

The invention discloses buprenorphine crystal forms and a preparation method thereof. The buprenorphine crystal forms comprise a crystal form I, a crystal form II, a crystal form III, a crystal form IV and a crystal form V. In the crystal forms, the crystal form I and the crystal form II are anhydrous crystal forms, the crystal form III is a 1, 4-dioxane solvate, the crystal form IV is a dimethyl carbonate solvate, and the crystal form V is an anisole solvate. Moreover, the stability of the buprenorphine crystal form I is obviously superior to that of a crystal form II, a crystal form III, a crystal form IV and a crystal form V; under the condition that the stability is obviously improved, the purity of the buprenorphine crystal form I is superior to that of an anhydrous crystal form II.
Owner:YANGTZE RIVER PHARM GRP CO LTD +1

Injectable buprenorphine formulation

The present invention provides an injectable liquid formulation comprising:a) a lipid controlled-release matrix comprising at least 50% triacyl lipids;b) at least one oxygen containing organic solvent;c) at least 16% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The invention further provides a controlled-release composition formed by administration of such an injectable liquid composition to a, preferably human, subject. The invention also provides a method of administration of buprenorphine to a subject comprising injecting such a liquid composition and a method for the treatment of pain, for opioid maintenance therapy or for the treatment of opioid dependence by detoxification and / or maintenance or for the treatment or prophylaxis of the symptoms of opioid withdrawal and / or cocaine withdrawal by injecting such a liquid composition.
Owner:CAMURUS AB

Treatment of autonomic dysfunction resulting from opioid use

PCT designated stage expiredWO2025010067A1Organic active ingredientsNervous disorderCatecholaminePartial Opioid Agonists
A method of treatment of a subject suffering from autonomic dysfunction due to opioid use is described. The autonomic dysfunction can be determined by, for example, detecting genetic damage, such as DNA hypermethylation, measuring catecholamine concentrations, collecting vitals data, and / or surveys. The method of treatment can include administering a partial opioid agonist, such as buprenorphine.
Owner:SMITH GENETICS RES LLC

Compositions And Methods For Making Benzylisoquinoline Alkaloids, Morphinan Alkaloids, Thebaine, And Derivatives Thereof

PendingUS20260125725A1TransferasesOxidoreductasesPurineMorphinone
Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (“BIAs”) such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and / or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthesis polypeptides, purine permeases, and polynucleotides encoding the same, are provided.
Owner:ANTHEIA INC

Preparation method of 7alpha [(S)-1-hydroxy-1, 2, 2-trimethylpropyl]-6, 14-bridge ethylidene-6, 7, 8, 14-tetrahydrothebaine

PendingCN121895325AOrganic chemistryBuprenorphine HydrochlorideThebaine
The invention discloses a preparation method of a buprenorphine hydrochloride key intermediate, particularly provides an improved method for preparing 7 alpha [(S)-1-hydroxy-1, 2, 2-trimethylpropyl]-6, 14-diethylidene-6, 7, 8, 14-tetrahydrothebaine, and belongs to the technical field of medical intermediates. The compound is a key intermediate for synthesizing buprenorphine hydrochloride. The solid of the key intermediate is obtained with high yield and high purity through the method, and the method is simple and convenient to operate and suitable for industrial production.
Owner:CHANGZHOU NO 4 PHARMA FACTORY +1

Stable pharmaceutical composition of buprenorphine and preparation method and use thereof

Provided is a pharmaceutical composition including buprenorphine, a derivative thereof, or a pharmaceutically acceptable salt thereof, a stabilizer, a biocompatible solvent, and at least one compound represented by Formula (IIA), (IIB) or (IIC), wherein R1 is hydrogen, a C1-C20 alkylcarbonyl group, or a C6-C18 arylcarbonyl group, and wherein the compound of Formula (IIA), (IIB) and (IIC) each have an amount of less than 1% w / w based on the total weight of the pharmaceutical composition during a shelf life of the pharmaceutical composition. Also provided is a method for preparing the pharmaceutical composition and a method for treating opioid addiction, pain, and / or depression in a subject in need thereof by administering the pharmaceutical composition to the subject.
Owner:ALAR PHARMA INC

BUPRENORPHINE EXTENDED-RELEASE PHARMACEUTICAL FORMS

UndeterminedCY1125854T1IsobutanolBenzoic acid
An injectable pharmaceutical composition comprising a solution of 3-acyl-buprenorphine or a pharmaceutical salt thereof in a biocompatible organic solvent, wherein the injectable pharmaceutical composition exhibits a sustained release profile lasting for more than one week when injected into a patient. The acyl group is an alkylcarbonyl group and an alkyl portion of the alkylcarbonyl group is straight chain, branched chain, having 1-20 carbon atoms. The biocompatible organic solvent is N-methyl-2-pyrrolidone, ethyl acetate, ethanol, butanol, 2-butanol, isobutanol, isopropanol, glycerin, benzyl benzoate, dimethyl sulfoxide, N,N-dimethylacetamide, propylene glycol, dimethyl glycol, benzyl alcohol, or a combination of two or more thereof.
Owner:ALAR PHARMA INC

Method of treatment and dosage forms thereof

The invention provides an oral dosage form comprising (i) an amount of oxycodone and (ii) an amount of buprenorphine, wherein the weight ratio of the amount of buprenorphine to the amount of oxycodone is greater than 1:40 calculated with the amount of buprenorphine in the dosage form expressed as the equimolar amount of buprenorphine base (Mw=467.64 g / mol) in mg, and the amount of oxycodone in the dosage form expressed as the equimolar amount of oxycodone hydrochloride (Mw=351.82 g / mol) in mg. The invention also provides combinations of an opioid agonist and buprenorphine for use to treat pain, wherein the combination achieves a reduction of adverse pharmacodynamic responses (such as, respiratory depression), compared with a corresponding stand-alone opioid therapy. The invention also includes methods of treatment and dosage forms thereof comprising such combinations.
Owner:PURDUE PHARMA LP

Abuse-resistant mucoadhesive devices for delivery of buprenorphine

PendingUS20250064796A1Nervous disorderAntipyreticAnti-inhibitorMucoadhesion
The present invention provides abuse deterrent mucoadhesive devices for delivery of buprenorphine. Each device comprises a mucoadhesive layer and a backing layer, and the pH in each layer is selected, such that absorption of buprenorphine is maximized.
Owner:BIODELIVERY SCIENCES INTERNATIONAL INC

Buprenorphine dosing regimens

The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.
Owner:INDIVIOR UK LTD

Compositions and methods for making benzylisoquinoline alkaloids, morphinan alkaloids, thebaine, and derivatives thereof

ActiveUS12416029B2TransferasesOxidoreductasesPurineMorphinone
Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (“BIAs”) such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and / or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthesis polypeptides, purine permeases, and polynucleotides encoding the same, are provided.
Owner:ANTHEIA INC

Treatment of chronic pain or gastrointestinal disorders using buprenorphine dimer

PCT designated stage expiredWO2025014912A1Nervous disorderOrganic chemistryDiseaseChronic pain
The present disclosure provides a method of treating a disease, e.g. chronic pain or IBS-D, in a subject in need thereof by orally administering: i) a therapeutically effective amount of a buprenorphine dimer; or ii) a pharmaceutical composition including a therapeutically effective amount of the buprenorphine dimer, wherein the buprenorphine dimer is represented by formula (I) or a pharmaceutically acceptable salt thereof. In particular, the buprenorphine dimer of formula (I) administered is in a neutral form. A process for preparing the buprenorphine dimer in the neutral form is also described.
Owner:DIMERX INC

Dopamine d3 receptor selective antagonists / partial agonists and uses thereof

Disclosed herein are novel methods of treating substance use disorders, mitigating the development of substance addiction, reducing the severity of substance withdrawal symptoms, or reducing or preventing substance relapse by providing to the patient a therapeutically effective amount of a Medication Assisted Treatment agent and a selective dopamine D3 receptor antagonist / partial agonist. In addition, the D3 antagonists / partial agonists described herein may be used to augment the effectiveness of current Medication Assisted Treatment regimens (e.g. methadone or buprenorphine) for the treatment of substance use disorders, including opioid use disorders.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES

Sublingual substance abuse disorder and Anti-addiction lozenge

Formulations and methods are described to produce sublingual substance abuse disorder and anti-addiction lozenges. The lozenges may include troche base, ketamine, and buprenorphine. The lozenges may include 0.25 weight percent to 2.53 weight percent ketamine and 0.61 weight percent to 4.88 weight percent buprenorphine. The methods may include placing troche base into a chamber and applying heat to the chamber to melt the troche base. The methods may include adding a first ingredient into the chamber and mixing the first ingredient into the melted troche base. The first ingredient may include ketamine. The methods may include adding a second ingredient into the chamber and mixing the second ingredient into the melted troche base with the first ingredient. The second ingredient may include buprenorphine. The methods may include pouring the melted mixture into a mold. The methods may include cooling the melted mixture in the mold to form the lozenge.
Owner:SYNERGISTIC THERAPEUTICS LLC

Preparation method and intermediates of multiple opioid drugs

The invention discloses a preparation method and intermediates of various opioid drugs. The invention provides a preparation method of various opioid drugs, and particularly provides a preparation method of a compound as shown in a formula A7 and a series of compounds as shown in a formula A6-2 and the like, the preparation method comprises the following steps: S10, under the action of a cyclization reagent, the compound as shown in the formula A6-2 is subjected to a cyclization reaction as shown in the following formula in an organic solvent, and the compound as shown in the formula A6-2 is obtained. The compound as shown in the formula A7 is obtained. A series of intermediates provided by the invention can be used for divergently synthesizing a plurality of opioid medicines, including naltrexone, nalmefene, nalbuphine, buprenorphine and the like. The preparation method provided by the invention has one or more of the following advantages: cheap and easily available raw materials, short synthesis steps, simple operation, easily amplified process and high product yield.
Owner:SHAOXING ZEJUN PHARMACEUTICALS CO LTD

Immunoassays for buprenorphine and metabolites

PCT designated stageWO2026177981A1Buprenorphine+NorbuprenorphineAntiendomysial antibodies
Disclosed herein are antibodies that specifically bind to buprenorphine and its metabolites norbuprenorphine, buprenorphine glucuronide and norbuprenorphine glucuronide analytes. Such antibodies can be used to detect a buprenorphine analyte in a sample, such as in a homogeneous enzyme immunoassay method. Hapten structures to elicit such antibodies and conjugates useful in immunoassays are also described.
Owner:ARK DIAGNOSTICS

Treatment of opioid use disorder, opioid withdrawal symptoms, and chronic pain

The current methods and compositions provide for a novel and effective therapeutic method for treating opioid use disorder, opioid withdrawal symptoms and / or chronic pain. Accordingly, certain aspects of the disclosure relate to a method for treating opioid use disorder, opioid withdrawal symptoms and / or chronic pain in a subject, the method comprising administering at least one purified cannabinoid compound and a partial opioid agonist. In some embodiments, the method comprises administering a composition comprising cannabidiol and buprenorphine.
Owner:RGT UNIV OF CALIFORNIA